45 completed. 45 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 45 | Completed 45 |
| Phase 2 | 4 | Completed 4 |
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer UGN-103 - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Completed | UroGen Pharma Ltd. | 99 | 2024-08-29 | 2026-10-22 |
| Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer Hexaminolevulinate Hydrochloride, Richard Wolf Photodynamic Diagnostic Equipment (PDD) system - Bladder Cancer | Phase 3 | Completed | Photocure | 158 | 2022-11-03 | 2024-10-03 |
| Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) UGN-102 - Bladder Cancer, Urothelial Carcinoma | Phase 3 | Completed | UroGen Pharma Ltd. | 8 | 2021-11-30 | 2024-09-19 |
| Immunological Response of Bladder Cancer Patients Under BCG Bacillus Calmette Guerin, PLACEBO - Bladder Cancer, Bacillus Calmette-Guerin | Phase 3 | Completed | University of Campinas, Brazil | 30 | 2021-09-03 | 2024-12-09 |
| A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Nivolumab, Radical cystectomy (RC), Bempegaldesleukin - Bladder Cancer, Bladder Tumor | Phase 3 | Completed | Bristol-Myers Squibb | 114 | 2020-02-05 | 2024-06-27 |
| Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor - Advanced Solid Tumors, NSCLC | Phase 3 | Completed | Dan Zandberg | 161 | 2019-11-15 | 2025-12-11 |
| Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866) Pembrolizumab, Gemcitabine, Cisplatin - Bladder Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 907 | 2019-06-13 | 2026-10-08 |
| En-bloc vs Conventional Resection of Primary Bladder Tumor En-Bloc TURB, Conventional TURB - Bladder Cancer | Phase 3 | Completed | David D'Andrea | 384 | 2019-02-28 | 2023-03-16 |
| A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Enfortumab Vedotin, Docetaxel, Vinflunine - Ureteral Cancer, Urothelial Cancer | Phase 3 | Completed | Astellas Pharma Global Development, Inc. | 608 | 2018-06-27 | 2026-01-09 |
| Photodynamic Diagnosis (PDD) in Flexible Cystoscopy hexaminoavolunate, WL cystoscopy - Bladder Cancer, Recurrence | Phase 3 | Completed | Jørgen Bjerggaard Jensen | 696 | 2016-02-01 | 2019-08-14 |
| A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting Hexaminolevulinate hydrochloride, KARL STORZ D-Light C PDD Flexible Videoscope System - Bladder Cancer | Phase 3 | Completed | Photocure | 304 | 2015-10-01 | 2018-07-02 |
| Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG Vicinium - Bladder Cancer | Phase 3 | Completed | Sesen Bio, Inc. | 133 | 2015-08-01 | 2023-07-24 |
| A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Docetaxel, Paclitaxel - Bladder Cancer | Phase 3 | Completed | Hoffmann-La Roche | 931 | 2015-01-13 | 2019-08-01 |
| A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy standard fluid management, fluid management guided by the EV1000 - Bladder Cancer | Phase 3 | Completed | Memorial Sloan Kettering Cancer Center | 282 | 2014-05-21 | 2024-03-20 |
| Tranexamic Acid During Cystectomy Trial (TACT) Tranexamic Acid, Placebo - Bladder Cancer | Phase 2 / Phase 3 | Completed | Ottawa Hospital Research Institute | 354 | 2013-06-01 | 2022-10-04 |
| Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer GEMCITABINE CISPLATINE, METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF - Bladder Cancer | Phase 3 | Completed | University Hospital, Rouen | 500 | 2013-02-01 | 2025-10-06 |
| Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer Surgery of percutaneous catheter system - Bladder Cancer | Phase 3 | Completed | Sun Yat-sen University | 186 | 2012-06-01 | 2024-11-05 |
| Randomized Trial Comparing Robotic and Open Radical Cystectomy open radical cystectomy, robotic-assisted radical cystectomy - Bladder Cancer | Phase 3 | Completed | Memorial Sloan Kettering Cancer Center | 124 | 2010-02-01 | 2020-03-16 |
| Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer selenium, placebo - Bladder Cancer | Phase 3 | Completed | KU Leuven | 276 | 2009-09-01 | 2016-05-12 |
| S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer gemcitabine hydrochloride, placebo - Bladder Cancer | Phase 3 | Completed | SWOG Cancer Research Network | 406 | 2007-09-01 | 2020-01-18 |
Showing 20 of 45. Sign in to see all of them.
Urinary Bladder Neoplasms (45) · Carcinoma, Transitional Cell (4) · Non-Muscle Invasive Bladder Neoplasms (4) · Urethral Neoplasms (4) · Anus Neoplasms (1) · Carcinoma in Situ (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Kidney Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Prostatic Neoplasms (1)
Female Urogenital Diseases (45) · Female Urogenital Diseases and Pregnancy Complications (45) · Male Urogenital Diseases (45) · Neoplasms (45) · Neoplasms by Site (45) · Urinary Bladder Diseases (45) · Urogenital Diseases (45) · Urogenital Neoplasms (45) · Urologic Diseases (45) · Urologic Neoplasms (45) · Carcinoma (8) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (8) · Urethral Diseases (4) · Genital Diseases (2)
5-aminolevulinic acid hexyl ester (6) · Gemcitabine (6) · Cisplatin (5) · Mitomycin (5) · Paclitaxel (5) · BCG Vaccine (4) · Doxorubicin (4) · Radiotherapy (4) · vinflunine (4) · Carboplatin (3) · Methotrexate (3) · Vinblastine (3) · Cystectomy (2) · Docetaxel (2) · Nivolumab (2)
Photocure (5) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Alliance for Clinical Trials in Oncology (2) · Bristol-Myers Squibb (2) · Eastern Cooperative Oncology Group (2) · Memorial Sloan Kettering Cancer Center (2) · Spectrum Pharmaceuticals, Inc (2) · UroGen Pharma Ltd. (2) · Astellas Pharma Global Development, Inc. (1) · Dan Zandberg (1) · David D'Andrea (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Hoffmann-La Roche (1) · Insel Gruppe AG, University Hospital Bern (1) · Institute of Cancer Research, United Kingdom (1)
United States (26) · Canada (12) · United Kingdom (12) · Belgium (9) · Italy (9) · Austria (8) · Denmark (8) · France (8) · Spain (8) · Germany (7) · Netherlands (7) · Poland (7) · Australia (6) · Israel (5) · Russia (5)
Bruce J. Roth, MD (2) · Shanta Chawla, MD (2) · Andreas Boehle, MD (1) · Anita L. Sabichi, MD (1) · Christoph Zielinski, MD (1) · Dan Zandberg, MD (1) · David C. Smith, MD (1) · David P. Wood, MD (1) · Dean Bajorin, MD (1) · Deepak M. Sahasrabudhe, MD (1)
PMID 29562804, PMID 33539743, PMID 15073851, PMID 16389183, PMID 18172274, PMID 18992952, PMID 19144456, PMID 19786668, PMID 20850152, PMID 21406089, PMID 21414125, PMID 21566413, PMID 22162575, PMID 22370319, PMID 22436453, PMID 22512481, PMID 23084842, PMID 23141049, PMID 23910233, PMID 23916692, PMID 24674149, PMID 25496767, PMID 26210894, PMID 26454620, PMID 27939400, PMID 28453896, PMID 29203268, PMID 29268948, PMID 29716640, PMID 29801011, PMID 29979488, PMID 31542806, PMID 33241650, PMID 33577729, PMID 33902955, PMID 34008425, PMID 35254888, PMID 35750559, PMID 35871040, PMID 37543464, PMID 38142702, PMID 38418343, PMID 39356537, PMID 41577609
2018 (2), 2014 (1), 2017 (1), P30CA008748 (1), U10CA032102 (1)